Almirall announces licensing agreement to accelerate antibody drug discovery
January 31, 2022Sales and Marketing
Almirall has announced a multi-target licensing agreement with Ablexis, focussed on licensing its AlivaMab Mouse technology, and a research collaboration …
Positive CHMP opinion for treatment of rare unpredictable disease
January 31, 2022Sales and Marketing
Blueprint Medicines has announced that the CHMP has adopted a positive opinion recommending to expand the current indication for AYVAKYT® …
CHMP recommends approval of dupixent for children with severe asthma
January 31, 2022Sales and Marketing
The EMA’s CHMP has adopted a positive opinion recommending the extension of the approval of Dupixent (dupilumab) for children with …
Supplemental NDA accepted for leukaemia treatment in China
January 28, 2022Medical Communications
BeiGene, focused on developing innovative and affordable medicines, announced that the Center for Drug Evaluation (CDE) of the China National …
India: DCGI approval for trialling of nasal COVID-19 vaccine
January 28, 2022Medical Communications
The Drugs Controller General of India (DCGI) has given permission to Bharat Biotech to conduct clinical trials for the use …
Launch of pioneering platform to accelerate mental health treatment discovery
January 28, 2022The clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, atai Life Sciences, has launched a platform …
The downfall of COVID-19 lies in new generation anti-viral drugs, says WHO
January 28, 2022Medical Communications
In a BBC News interview, WHO shared their views against easing pandemic restrictions, as new variants flare up anywhere until …
Oncology history: Immunocore claims first-ever FDA approval of melanoma drug
January 27, 2022Business Services
Immunocore has claimed a piece of history in biotech industry, becoming the first company to secure an FDA approval for …
Gilead combo therapy hit with FDA hold over serious adverse events
January 27, 2022Business Services
The FDA has placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus …
Face mask rules and COVID-19 passes end in England, care home restrictions ease
January 27, 2022Business Services
The government has announced that there will be no limit on the number of visitors to care homes in England. …
Medidata partners with Circuit Clinical to strengthen clinical trial capabilities
January 27, 2022Business Services
Medidata has announced a partnership with Circuit Clinical to strengthen its decentralised clinical trial (DCT) capabilities. Circuit Clinical has created …
FDA clearance of Investigational New Drug Application for novel peanut allergy vaccine
January 26, 2022Research and Development
Allergy Therapeutics has announced the FDA clearance of the Investigational New Drug Application (IND) for its novel virus-like particle (VLP)-based …
Highest UK COVID-19 deaths since February as Pfizer begin trials for Omicron jab
January 26, 2022Research and Development
Pfizer has begun clinical trials for its new COVID-19 vaccine tailored to the Omicron variant, and has shared that it …
Maxim Biomedical receives EUA for ClearDetect COVID-19 antigen home test
January 26, 2022Research and Development
Maxim Biomedical have received an Emergency Use Authorisation (EUA) from the FDA for their new ClearDetect COVID-19 Antigen Home Test. …
New study highlights cell power as a functional biomarker for preventing tumour escape
January 26, 2022Research and Development
LUMICKS announced that new research findings published in Translational Medicine detailed a novel design strategy for preventing tumour escape through …
FDA grants Evrysdi priority review for treatment of spinal muscular atrophy in infants
January 25, 2022Manufacturing and Production
The FDA has granted priority review of a supplemental new drug application (sNDA) for Evrysdi (risdiplam), to expand the indication …
Significantly reduced tumour growth with new candidate
January 25, 2022Manufacturing and Production
Spago Nanomedical AB announced new clinical and preclinical results for the company’s leading candidate drug, Tumorad® (177Lu-SN201). In a preclinical …
Bimzelx approved in Japan for treatment of multiple types of psoriasis
January 25, 2022Manufacturing and Production
UCB announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorisation for BIMZELX (bimekizumab) for …
FDA restrict use of two monoclonal antibody treatments
January 25, 2022Manufacturing and Production
The FDA has shared that it is limiting the use of two monoclonal antibody therapies for the treatment of COVID-19, …
Ascletis begins Phase III trial into bevacizumab for treatment of recurrent glioblastoma
January 24, 2022Sales and Marketing
Ascletis Pharma has announced the dosing of the first patient in the Phase III registration clinical trial of ASC40, combined …
Latest content
